Figure 4From: Increased PADI4 expression in blood and tissues of patients with malignant tumors Levels of PADI4 and cAT in plasma of patients with various tumors. Plasma samples are listed as the followings: lane 1–4 breast carcinoma (n = 112), after receiving surgery (n = 86), breast fibroadenomas controls (n = 30), and health controls (n = 42); 5–10 hepatocellular carcinomas (n = 77), after receiving surgery (n = 24), hepatitis A controls (n = 28), hepatitis B controls (n = 14), liver cirrhosis controls (n = 27), and healthy controls (n = 42); 11–14 lung cancer (n = 127), after receiving surgery (n = 24), pulmonitis controls (n = 48), and healthy controls (n = 31); 15, 16 esophageal carcinomas (n = 64) and healthy controls (n = 44); 17–21 gastric cancer (n = 94), after receiving surgery (n = 43), chronic gastritis controls (n = 31), acute appendicitis controls (n = 22), and healthy controls (n = 38); 22–24 colon cancer (n = 21), after receiving surgery (n = 15), and healthy controls (n = 17); 25–27 rectal cancer (n = 19), after receiving surgery (n = 28), and healthy controls (n = 17); 28–31 pancreatic cancer (n = 21), after receiving surgery (n = 6), acute pancreatitis controls (n = 7), and healthy controls (n = 60); 32–34 ovarian carcinomas (n = 29), after receiving surgery (n = 11), and healthy controls (n = 23); 35, 36 prostate cancer (n = 18) and healthy controls (n = 23),; 37–39 renal cell carcinomas (n = 19), chronic nephritis controls (n = 11), and healthy controls (n = 60); 40, 41 bladder carcinomas (n = 10) and healthy controls (n = 23); 42–46 cervical cancer (n = 24), endometrial carcinomas (n = 15), uterine myomas (n = 34), cervicitis (n = 15), and healthy controls (n = 34); 47–49 thyroid carcinomas (n = 7), thyroid adenomas (n = 16), and healthy controls (n = 36).Back to article page